SureTrader
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 2/24/2018 12:41:02 PM - Followers: 745 - Board type: Free - Posts Today: 28

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

2017 MILESTONES:



Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
IPIX News: Quarterly Report (10-q) 02/07/2018 04:59:15 PM
IPIX News: Amended Statement of Ownership (sc 13g/a) 01/11/2018 04:35:53 PM
IPIX News: Statement of Changes in Beneficial Ownership (4) 12/27/2017 03:08:40 PM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
PlusOneCoin Top Posts
#217196   your statement is still misleading as the trades TheHound 02/12/18 11:03:51 PM
#216960   You've made the argument for Kevetrin continuous intravenous biodoc 02/11/18 01:24:43 PM
#217973   B-OM Due Diligence sox040713 02/18/18 03:28:08 PM
PostSubject
#217582  Sticky Note $IPIX CATALYST RADAR FOR Innovation Pharmaceuticals Inc. BooDog 02/15/18 10:14:35 AM
#217318  Sticky Note Some of you may be wondering how people PlentyParanoid 02/13/18 02:08:35 PM
#216887  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patents sox040713 02/10/18 02:44:19 PM
#214633  Sticky Note For B-OM, 5-10M upfront 20-40M if approved and BioHedge 01/29/18 11:38:05 AM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#218893   Wow! Things must be getting close! When Focusakker 02/24/18 12:41:02 PM
#218892   Hell, I'd settle for Leo finding the cards. choctaw 02/24/18 12:13:04 PM
#218891   I know, but the person I replied to TheDane 02/24/18 12:10:40 PM
#218890   PHARMA PRESSURE GAGE reads Watch out! HIGH PRESSURES. HIGH. Echo20 Echo20 02/24/18 12:10:32 PM
#218889   ipix IF AND WHEN THERE ARE OFFERS TO IPIX: Echo20 02/24/18 12:05:30 PM
#218888   I hear you. I try hard to not LilyGDog 02/24/18 11:56:49 AM
#218887   Wrong! There are no encrypted phones Detonate 02/24/18 11:47:58 AM
#218886   Echo, This may have the information for which you georgejjl 02/24/18 11:44:06 AM
#218885   3 catalysts to 2018 remain. P results, OM Rdunn88 02/24/18 11:40:35 AM
#218884   SCOTTWNYK PLEASE POST THE CRITERIONS YOU USED TO FIND Echo20 02/24/18 11:36:28 AM
#218883   Prurisol for the treatment of breast cancer, psoriasis, georgejjl 02/24/18 11:24:18 AM
#218882   They're not the CIA. There are no encrypted frrol 02/24/18 11:16:17 AM
#218881   IPIX Did anyone bother to check on the number Echo20 02/24/18 11:07:34 AM
#218880   Dane On your J& J comments: Echo20 02/24/18 11:05:09 AM
#218879   Does it matter now? What matters is what results Amatuer17 02/24/18 10:56:17 AM
#218878   I haven't read that PR since the trial Scottwny 02/24/18 10:51:27 AM
#218877   I evaluate my IPIX long position daily. Detonate 02/24/18 10:33:25 AM
#218876   AN ABSOLUTE MUST READ!!! georgejjl 02/24/18 10:16:06 AM
#218875   SCOTTWNY I think Dr. Bertolino answers runninggirl2016 02/24/18 09:07:08 AM
#218874   This is a touchy time for management. The frrol 02/24/18 08:51:26 AM
#218873   We really should not be pestering management. They frrol 02/24/18 08:47:30 AM
#218872   Regardless of who answers the phones, P results Rdunn88 02/24/18 08:12:41 AM
#218871   Which rabbit hole shall we enter today? Non-answered TheDane 02/24/18 07:59:45 AM
#218870   I agree. Leo in his early days was LilyGDog 02/24/18 07:50:33 AM
#218869   The conversation about calling the company and leaving cybermich 02/24/18 04:19:07 AM
#218868   sounds about right vip1999 02/24/18 12:46:15 AM
#218867   They are probably over seas securing a licensing septmike09 02/24/18 12:39:35 AM
#218864   kfc, did you leave a email message as vip1999 02/23/18 11:49:38 PM
#218863   B-UP Blogs sox040713 02/23/18 11:40:56 PM
#218861   No I will stick around. Just put them septmike09 02/23/18 10:52:56 PM
#218859   Are you out of here? kfcyahoo 02/23/18 10:44:04 PM
#218855   Leo E called me back(thanks to a poster kfcyahoo 02/23/18 10:37:32 PM
#218853   I look at the situation like this - Here Today 02/23/18 10:31:44 PM
#218852   The K 2 patient trial cost 300k, wasted Rdunn88 02/23/18 10:30:30 PM
#218850   So you were able to speak to Leo Here Today 02/23/18 10:22:24 PM
#218848   Mako’s empty office claim proved right after all. Rdunn88 02/23/18 10:19:15 PM
#218847   My second attempt to call was today. My kfcyahoo 02/23/18 10:15:30 PM
#218846   Jules, yes, that was the number I called kfcyahoo 02/23/18 10:10:13 PM
#218845   Bertolino starts with a capital "B". ;0 keltoi 02/23/18 09:48:23 PM
#218844   I don't know about any of you, but Here Today 02/23/18 09:47:01 PM
#218843   Did you try (978) 921-4125? Jewelsoftheworld 02/23/18 09:44:40 PM
#218842   February 8, 2018 Williamsc 02/23/18 09:43:32 PM
#218840   I see what you mean. So the question septmike09 02/23/18 09:40:04 PM
#218837   Mike, What does Bertolino start with? kfcyahoo 02/23/18 09:28:31 PM
#218836   Right so that would be Bertolino. Not B. septmike09 02/23/18 09:11:15 PM
#218835   Please enter the name of the party you kfcyahoo 02/23/18 09:09:02 PM
#218834   KarinCA, Georgejjl, or Septmike09, kfcyahoo 02/23/18 09:04:35 PM
#218833   Did the answering machine ever identify someone by septmike09 02/23/18 09:04:09 PM
#218832   "They're not going to give you non-public info kfcyahoo 02/23/18 08:59:14 PM
#218831   “the 2nd attempt for the operator(press 0) resulted scottsmith 02/23/18 08:52:13 PM
PostSubject